Outcomes research defines ‘value’ from all perspectives Tracey Langsdale Newsletter Article 16 February 2013 Pages: 3 - 4
Patients cannot afford HMG CoA reductase inhibitors, or can they? Newsletter Article 16 February 2013 Pages: 4 - 4
Quality assurance programme alters the choice of thrombolytics Newsletter Article 16 February 2013 Pages: 7 - 7
Prophylactic sulbactam/ampicillin or cefoxitin for abdominal surgery? Newsletter Article 16 February 2013 Pages: 7 - 7
The cost effectiveness of prophylaxis for bacterial endocarditis Newsletter Article 16 February 2013 Pages: 8 - 8
Cystic fibrosis carrier screening would not save money Newsletter Article 16 February 2013 Pages: 10 - 11
Education improves QOL in patients with Parkinson’s disease Newsletter Article 16 February 2013 Pages: 11 - 11
QOL with vinorelbine vs fluorouracil/ calcium folinate in NSCLC Newsletter Article 16 February 2013 Pages: 12 - 12
An approach for managing the use of new, costly medicines Newsletter Article 16 February 2013 Pages: 13 - 13
Anticipate further public health problems with schizophrenia Newsletter Article 16 February 2013 Pages: 15 - 15